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INTRODUCTION
Gamma-aminobutyric acid type A receptors 
(GABAARs) are ligand gated ion channels mediating 
most of the inhibitory actions of the neurotransmitter 
gamma-aminobutyric acid (GABA) in the central ner-
vous system (Korpi at al. 2002). These receptors are 
comprised of several subunits (α1-6, β1-3, γ1-3, δ, ε, θ, 
π), mostly being pentamers assembled of two α, two β 
and one γ subunit (Rudolph at al. 1999). Nevertheless, 
different subunit composition, especially the presence 
of a particular α subunit, is essential for the functional 
and pharmacological properties of these receptors 
(Olsen and Sieghart 2008). GABAARs are expressed 
throughout neurons and glial cells and are involved in 
many brain functions, as well as being the targets for a 
large number of therapeutics in clinical use: benzodi-
azepines (BZ), barbiturates, neurosteroids, and general 
anesthetics.
Zolpidem acts as a positive allosteric modulator at 
the benzodiazepine binding site of GABAAR, although 
chemically it is not a benzodiazepine but an imida-
zopyridine (Sanger and Zivkovic 1986). Studies on 
affinity and functional efficacy indicated that zolpi-
dem is selective for GABAARs containing α1 subunits, 
having intermediate affinity for receptors containing 
α2 or α3 subunits, and lacking interactions with α5- 
GABAARs (Depoortere at al. 1986, Sanna at al. 2002). 
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Genetic studies of knock-in mice confirmed the pref-
erential affinity of zolpidem for the α1 subunit of 
GABAARs (Crestani at al. 2000), consequently exert-
ing a pronounced hypnotic effect. Zolpidem also has 
mild anxiolytic and myorelaxant effects (Depoortere 
at al. 1986, Sanger at al. 1996), as well as anticonvul-
sant activity (Crestani at al. 2000, Fradley at al. 2007, 
Pericic at al. 2008, Vlainic and Pericic 2010). Acting 
as hypnotic zolpidem is used in clinics for the treat-
ment of insomnia characterized by inability to initiate 
sleep. Zolpidem is slowing activity in the brain to 
allow and maintain sleep (for review see Fitzgerald at 
al. 2014). Until recently, zolpidem was considered 
devoid of adverse effects upon short term use and in 
recommended clinical doses. Nevertheless, there is an 
increasing body of evidence that long term adminis-
tration of zolpidem in rodents induces development of 
tolerance and dependence (Auta at al. 2008, Vlainic 
and Pericic 2009, Murphy at al. 2011, Wright at al. 
2014); and numerous cases of zolpidem abuse and 
dependence have been reported in humans, especially 
those having a history of drug and/or alcohol abuse 
(for review see Victorii-Vigneau at al. 2013). Recent 
paper summarized current knowledge on zolpidem’s 
action underlying the distinct role of different 
GABAARs in dependence (Fitzgerald at al. 2014). 
Namely, the development of tolerance and dependence 
following repeated zolpidem treatment, and the pres-
ence of withdrawal syndrome are likely accompanied 
with different neuroadaptive changes in the GABAergic 
system, mainly leading to alterations in receptor 
expression and/or function (for review see Uusi-
Oukari and Korpi 2010). Despite many studies, the 
molecular mechanisms involved in the development of 
tolerance to the actions of zolpidem are still unknown. 
Since it is indicated that changes in GABAergic sys-
tem are dose and time dependent (for review see Uusi-
Oukari and Korpi 2010) it is of importance to study 
different treatment time points. In the current study 
we investigated the effects of chronic zolpidem treat-
ment (7 days) and different withdrawal periods (24, 
48, 72 and 96 h) on the number and on the expression 
of GABAAR subunit mRNAs. The study is conducted 
on recombinant α1β2γ2S GABAARs (the most abun-
dant receptor subtype) stably expressed on the surface 
of HEK 293 cells. Shaw and colleagues (2002) showed 
that HEK 293 cells express many proteins typically 
found in neurons, although the transcription of trans-
fected genes encoding GABAAR subunits could be 
differently regulated than in vivo or in primary neu-
ronal culture where endogenous genes are involved as 
well. Thus, well-defined subunit composition of the 
recombinant receptors offers some advantages, e.g. 
homogenous population of receptors, well defined 
receptor subtype, which are at the same time limita-
tion factors. 
METHODS
Cell culture
The human embryonic kidney (HEK) 293 cell line 
stably expressing the α1β2γ2S subtype of GABAA 
receptor was kindly donated by Dr. David Graham 
(Besnard at al. 1997). The cells were maintained 
according to standard cell culture techniques in 
Dulbecco’s modified Eagle’s medium supplemented 
with 10% heat-inactivated foetal bovine serum, 2 mM 
L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin at 37°C in humidified air with 5% CO2. 
Culture medium, antibiotics, fetal bovine serum and 
other chemicals were supplied from commercial sup-
pliers.
Drug treatment
Cells were seeded into new flasks and grown for 
three days prior to exposure to drugs (zolpidem 
(N,N,6-trimethyl-2-(4-methylphenyl)-imidazo(1,2-a)
pyridine-3-acetamide) was a generous gift from Pliva, 
Zagreb, Croatia). Control cells were treated with 1 
µM GABA and vehicle (zolpidem and GABA were 
dissolved in distilled water) and underwent with-
drawal as well. Since we studied the effect of the drug 
during seven consecutive days the medium contain-
ing zolpidem (10 µM) and GABA (1µM) was replaced 
every third day with fresh medium. In withdrawal 
studies the medium containing zolpidem was replaced 
with drug-free medium at the day withdrawal started 
and incubated for additional period of time (24, 48, 72 
or 96 h, respectively) in the presence of 1 micromolar 
GABA.
In order to address the issue of prolonged culturing 
to the changes in the maximum number of benzodiaz-
epine binding sites, the allosteric linkage between 
GABA and benzodiazepine binding sites at the 
recombinant GABAARs, and the expression of sub-
unit mRNAs, there were a groups of cells cultured 
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with the vehicle for seven days that experienced 24, 
48, 72 and 96 hours of vehicle withdrawal, respec-
tively. Since we found no changes in the parameters 
assessed in this study in the control withdrawal 
groups the results obtained are not presented. 
Moreover, a general trophic effect of zolpidem treat-
ment on the growth of HEK 293 cells could presum-
ably be excluded because total cellular proteins did 
not vary between control and zolpidem-treated as 
well as control- and zolpidem- withdrawn group of 
cells (data not shown). 
Radioligand binding studies
Preparation of the membranes. Membranes from 
stably transfected HEK293 cells were prepared mainly 
as described elsewhere (Pericic at al. 2005). The cells 
were washed with phosphate-buffer saline, scraped 
from flasks and centrifuged at 12 000×g for 12 min. 
The cell pellet was homogenized in 50 mM Tris-citrate 
buffer (pH 7.4) by 10 strokes at 1000×g using teflon 
pestle and a glass homogenizer, and then centrifuged 
at 200 000×g for 20 min. The same re-suspension/cen-
trifugation procedure was repeated twice. Finally the 
pellet was re-suspended and stored in aliquots at 
−20°C. The suspension of the cell membranes was 
centrifuged on the day of binding assay at 200 000×g 
for 20 min. 
[3H]flunitrazepam binding assay. Aliquots of the 
cell membrane preparation (~100 µg protein) were 
incubated in a 50 mM Tris-citrate buffer supplemented 
with 150 mM NaCl at 4°C for 90 min (Pericic at al.. 
2005) with the addition of varying concentrations of 
non-radioactive flunitrazepam (ten final concentra-
tions in the range 0.4–50 nM) and a fixed concentra-
tion (1 nM) of [3H]flunitrazepam ([3H]flunitrazepam 
(specific activity 87 Ci/mmol) was purchased from 
Amersham Biosciences UK Ltd.). In stimulation stud-
ies, varying concentrations of GABA (1 nM–1 mM) 
were incubated with [3H]flunitrazepam (1 nM). Non-
specific binding was determined in the presence of 100 
µM diazepam. Total assay volume of all binding stud-
ies was 0.5 ml. The radioactivity bound to membranes 
was counted on a LSC counter (Wallace 1409DSA) 
after a rapid vacuum filtration on Whatman GF/C fil-
ters.
Protein determination. Using bovine serum albumin 
as a standard, protein concentration was determined in 
10 µl samples of membrane suspension.
Conventional RT-PCR 
Total cellular RNA was extracted using a ReliePrep 
RNA Cell Miniprep System (Promega, Germany) and 
quantified at 260 nm using spectrophotometer 
(NanoDrop, Thermo Scientific). Reverse transcription 
and semi-quantitative PCR were performed as previ-
ously described (Jazvinscak Jembrek at al. 2012). Briefly, 
together with random hexadeoxynucleotide primers (2.5 
μM), total RNA (1 μg) was denatured at 65°C for 5 min, 
Table I
Primer sequences and number of cycles used for PCR amplification
Gene Sequence description (5′ – 3′) Cycle numbers Amplicon size (bp)
β-actin
TCA CCA ACT GGG ACG ACA TG
24, 25 150
TTC GTG GAT GCC ACA GGA CT
α1
AGC TAT ACC CCT AAC TTA GCC AGG
20, 21 304
AGA AAG CGA TTC TCA GTG GAG AGG
β2
TGA GAT GGC CAC ATC AGA AGC AGT
17, 18 317
TCA TGG GAG GCT GGA GTT TAG TTC
γ2S
AAG AAA AAC CCT GCC CCT ACC ATT
20, 21 336
TTC GTG AGA TTC AGC GAA TAA GAC
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and the first strand of cDNA was synthesized by adding 
the following reagents: reverse transcription buffer 
(Invitrogen), 0.5 mM dNTPs (Takara, Japan), 40 U of 
RNase-inhibitor (Roche, USA) and 200 U of SuperScript 
ІІ reverse transcriptase (Invitrogen, USA). For DNA 
synthesis, after primer annealing (25°C, 10 min), the 
reaction mixture was incubated at 42°C for 50 min and 
then heated (70°C, 15 min) for enzyme inactivation. 
Each RT reaction had two negative controls: the sample 
without SuperScript ІІ reverse transcriptase and the 
sample without the RNA template to test for contamina-
tion with genomic DNA. The resulting cDNA (1:10 dilu-
tion) was amplified using EmeraldAmp MAX PCR 
Master Mix (Takara, Japan) with added primers (0.2 
μM). The reactions were performed for a determined 
number of cycles (cDNA was amplified and analyzed in 
two consecutive cycles in the logarithmic phase of PCR 
reaction; Table I) each consisted of 95°C for 30 s, 60°C 
for 30 s and 72°C for 1 min, with a final extension at 
72°C for 7 min. The reaction products were separated by 
electrophoresis on a 1.5% agarose gels and visualized by 
EtBr staining. Maximal optical density was obtained 
using the ImageJ software (NIH, USA). The expression 
of GABAAR subunits mRNA was normalized to the 
reference gene β-actin mRNA expression and compared 
between control and treated groups. 
Data analysis
The analysis of binding data was performed using 
the GraphPad Prism (GraphPad Software, USA). The 
values Kd and Bmax were obtained by nonlinear regres-
sion using the equation for a hyperbola (one binding 
site): Y = Bmax× X / (Kd + X), where Kd is the concentra-
tion of ligand required to reach half-maximal binding 
and Bmax is the maximum number of binding sites. The 
percentage of change in [3H]flunitrazepam binding 
produced by GABA was defined as (specific binding 
in the presence of GABA/specific binding in the 
absence of GABA)×100. The enhancement curves, 
analyzed using the sigmoidal equation, determined the 
values for half-maximum (EC50) and the maximum 
enhancement (Emax, defined as absolute difference 
between the top and bottom plateau) of GABA-induced 
[3H]flunitrazepam binding. 
Statistical evaluation was performed with one-way 
analysis of variance (ANOVA) followed by a post-hoc 
Dunnett’s multiple comparison test. All data are 
expressed as means±SEM of at least three independent 
experiments performed in duplicate. P-values of equal 
or less than 0.05 were considered significant.
RESULTS
The number of benzodiazepine binding sites 
following chronic zolpidem treatment and its 
withdrawal in HEK 293 cells stably transfected 
with α1β2γ2S subunits of GABAARs
Chronic zolpidem treatment (10 μM, 7 days) and its 
withdrawal (24, 48, 72 or 96 h, respectively) were stud-
ied with respect to the number and the affinity of ben-
zodiazepine binding sites in the recombinant α1β2γ2S 
GABAARs. Control cells were treated with the vehicle 
and GABA (1 μM). In order to asses the possible influ-
ence of prolonged culturing and withdrawal on the 
maximum number of [3H]flunitrazepam binding sites 
in the GABAAR complex, the control groups of cells 
Table II
The dissociation constant (Kd) of benzodiazepine binding sites following zolpidem treatment and its withdrawal at 
recombinant GABAAR
Affinity of [3H]flunitrazepam binding sites (nM)
Control 3.72±0.44
Zolpidem 7 days 4.49±0.61
+ withdrawal 24 h 4.51±0.56
+ withdrawal 48 h 4.05±0.60
+ withdrawal 72 h 2.98±0.95
+ withdrawal 96 h 2.57±0.30
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also experienced withdrawal. The experiments revealed 
no changes in the maximum number of benzodiaz-
epine binding sites and the dissociation constant 
between control groups (data not shown).
Saturation isotherms and Scatchard plots of binding 
studies are shown in Figure 1. The maximum number 
of benzodiazepine binding sites (Bmax) in the group 
treated with zolpidem for 7 days (5.32±0.82 pmol/mg 
protein) was unchanged when compared to the control 
group (4.91±0.82 pmol/mg protein). No change in the 
maximum number of benzodiazepine binding sites was 
also observed for withdrawal periods that lasted 24- 
(4.08±0.30 pmol/mg protein), 48- (4.79±0.64 pmol/mg 
protein) and 72-hours (4.90±0.33 pmol/mg protein). On 
the other hand, the maximum number of benzodiaz-
epine binding sites was augmented in the group where 
the withdrawal period lasted 96 hours (8.67±0.99 pmol/
mg protein). One-way ANOVA revealed the signifi-
cance between the above mentioned groups (F5,16=4.83; 
P<0.01) (Fig. 2). Namely, in the group where zolpidem 
treatment was withdrawn for 96 hours the maximum 
number of [3H]flunitrazepam binding sites was signifi-
cantly augmented (P<0.05, post hoc Dunnett’s Multiple 
Comparison test) when compared to the control group, 
but also when compared to zolpidem treated and other 
zolpidem-withdrawn groups (24, 48 and 72 h, respec-
tively). Upregulation of maximum number of benzodi-
azepine binding sites following 96 h zolpidem with-
drawal was observed when lower zolpidem concentra-
tion (1 μM) was applied but the results were at the 
border of significance and thus not shown.
Kd is the equilibrium dissociation constant or bind-
ing affinity constant and is the reciprocal value of the 
affinity. The affinity of benzodiazepine binding sites 
in zolpidem treated and withdrawn groups remained 
unchanged (versus control group) although one could 
notice that the dissociation constant of [3H]flunitraze-
pam binding sites is slightly decreased across groups 
withdrawn from zolpidem especially when withdrawal 
lasted 96 hours (Table II). 
The expression of mRNA of GABAAR subunits 
following zolpidem treatment and different 
withdrawal periods
In order to asses the influence of chronic zolpidem 
treatment (10 μM, 7 days) and its withdrawal (24, 48, 72 
or 96 h, respectively) on the expression of GABAR sub-
unit mRNA,  the amount of α1, β2 and γ2S mRNA was 
determined by conventional RT-PCR analysis (see 
sequence description in Table I). The amplification 
products for the housekeeping gene β actin and receptor 
subunits had the expected molecular size. Since there 
was no product in the negative control, the contamina-
tion of RNA samples and/or PCR preparation was ruled 
out. In addition, to assess the influence of prolonged 
culturing the control groups of cells also underwent 
withdrawal (control groups were cultured with vehicle 
Fig. 1. The effect of zolpidem treatment and different with-
drawal periods on saturation isotherms and Scatchard plots 
of [3H]flunitrazepam binding sites on the membranes of 
HEK 293 cells stably transfected with α1β2γ2S subunits of 
GABAARs. Cell membranes of zolpidem (10 μM, seven 
days) treated and withdrawn (24, 48, 72 and 96 hours) 
groups were incubated with increasing concentrations of 
non-radioactive flunitrazepam (0.3–50 nM) in the presence 
of 1 nM [3H]flunitrazepam. Control cells were treated with 
the vehicle and 1 micromolar GABA as treated groups.
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for seven days and then 24, 48, 72 and 96 hour with-
drawal). The data for these control groups are not shown 
since there were no changes in the expression level for 
the α1, β2 and γ2S mRNAs between them. 
As shown in Figure 3, the mRNA levels for all three 
subunits (α1, β2 and γ2S) were not changed either by 
zolpidem treatment (7 days, 10 μM) or by withdrawal 
periods that lasted for 24, 48, or 72h, respectively. 
Unchanged levels of β2 subunit mRNA were observed 
also for 96-hours withdrawal period in comparison to the 
control group. On the other hand, statistical analysis using 
one-way ANOVA revealed significant differences for α1 
(F5,71=3.775; P=0.0044) and γ2S (F5,63=2.991; P=0.017) but 
not for β2 (F5,60=0.813; P=0.544) mRNA levels within the 
zolpidem treated and withdrawal groups. Namely, mRNAs 
for α1 (P<0.01, post hoc Dunnett’s Multiple Comparison 
test) and γ2S (P<0.05, post hoc Dunnett’s Multiple 
Comparison test) subunits were significantly increased 
following a 96-hour withdrawal period when compared to 
the mRNA in the control group. 
GABA induced enhancement of [3H]
flunitrazepam binding to recombinant 
GABAARs following zolpidem treatment and 
different withdrawal periods
The effect of chronic zolpidem treatment (7 days, 10 
μM) and its withdrawal (24, 48, 72 and 96 h) on GABA 
potentiation of [3H]flunitrazepam binding as a mea-
sure of degree of allosteric coupling between the 
GABA and benzodiazepine binding site at GABAAR 
complex was studied at membranes of HEK 293 cells 
stably transfected with α1β2γ2S recombinant 
GABAARs. Control cells were treated with the vehicle 
and GABA (1 μM). Moreover, the control groups of 
cells also underwent withdrawal and since there were 
no changes in any parameters assessed the data 
obtained are not shown.
One-way ANOVA followed by Dunnett’s multi-
ple comparison test revealed significant differences 
between these groups (F5,16=30.90; P=0.0001). The 
addition of GABA (1 nM–1 mM) to membranes 
obtained from control and zolpidem treated and 
withdrawn cells enhanced [3H]flunitrazepam (1 
nM) binding in a concentration dependent manner. 
On the other hand, analyses of the enhancement 
curves (Fig. 4A) for the control, zolpidem treated 
and withdrawal groups did not show differences in 
the concentrations of GABA that produced a half-
maximum enhancement of [3H]flunitrazepam bind-
ing (EC50). In order to point out the differences in 
the intensity of GABA-induced enhancement of 
[3H]flunitrazepam binding the data are presented as 
the percentage of their own basal values (Fig. 4A) 
and as the maximum enhancement (Emax) (Fig. 4B). 
The maximum enhancement of [3H]flunitrazepam 
binding produced by GABA in the control group was 
64.3±1.8% indicating that the GABA binding sites 
were functionally coupled to the benzodiazepine bind-
ing sites. In the zolpidem treated group the maximum 
enhancement of benzodiazepine binding (53.7±2.4%) 
was significantly (P<0.05) lower compared to the con-
trol group. As shown in Figure 4, the results obtained 
indicated that zolpidem withdrawal (24, 48, 72 and 96 
h) also leads to a significant decline (P<0.01 and 
P<0.05) in the level of allosteric coupling between 
GABA and benzodiazepine binding sites at GABAAR 
complex having maximum enhancements of app 53, 
52, 47 and 33%, respectively. 
Changes in the level of allosteric coupling were 
observed when the cells were treated with 1 micromo-
Fig. 2. The effect of zolpidem treatment and different with-
drawal periods on the maximum number (Bmax) of [3H]fluni-
trazepam binding sites on the membranes of HEK 293 cells 
stably transfected with α1β2γ2S subunits of GABAARs. Cell 
membranes of zolpidem (10 μM, seven days) treated and 
withdrawn (24, 48, 72 and 96 hours) groups were incubated 
with increasing concentrations of non-radioactive flunitraze-
pam (0.3–50 nM) in the presence of 1 nM [3H]flunitraze-
pam. Bmax was obtained by nonlinear regression. The results 
are expressed as means ± SEM (n=3). *P<0.05 versus con-
trol group (ANOVA followed by the Dunnett’s test). 
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lar zolpidem concentration as well, although they were 
at the border of significance (data not shown).
DISCUSSION
To address the timeframe of the changes induced by 
chronic zolpidem treatment and withdrawal we exposed 
cells stably expressing recombinant GABAARs to 
zolpidem (10 μM) for seven days. Withdrawal periods 
lasted 24, 48, 72 and 96 hours, respectively. Our results 
demonstrate that zolpidem treatment and 24-, 48- and 
72-hour withdrawal produced no changes in the num-
ber of [3H]flunitrazepam binding sites while following 
96-hour withdrawal there was an increase in the num-
ber of benzodiazepine binding sites in our system (Fig. 
1). Similar was observed when the cell culture was 
treated with 1 micromolar zolpidem upon the same 
treatment regime but the results were on border of sig-
nificance (data not shown).
When we related obtained with the previous results, 
we assumed that detected [3H]flunitrazepam binding 
sites are probably expressed on the cell surface (Pericic 
at al. 2007, Svob Strac at al. 2008, Vlainic at al. 2010). 
There is also no change in the levels of α1, β2 and γ2S 
subunit mRNAs following zolpidem treatment and 
withdrawal that lasted 24, 48 or 72 hours. Follesa and 
colleagues (2002) showed that long-term exposure of 
rat cerebellar granule neurons to zolpidem (10 μM) 
does not produce any significant changes in the abun-
dance of mRNA for α1/4, β1/2/3 and γ2 subunits. 
Moreover, in several animal studies seven-day zolpi-
dem treatment in rats had no effect on α1 and γ2 
mRNA expression (Holt at al. 1997, Wright at al. 
2014).
Altered number of binding sites for a particular drug, 
e.g. benzodiazepines, could account for changes in drug 
action, for instance the need for a greater amount of the 
drug in order to produce the needed action in the same 
proportion. Namely, 10 days of zolpidem treatment pro-
duced tolerance to its anticonvulsant, hypothermic and 
ataxic effects as well as withdrawal-like symptoms 
after drug termination (Auta at al. 2008, Vlainic and 
Pericic 2009, Wright at al. 2014). Although the most 
persuasive premise for decreased sensitivity of 
GABAARs after prolonged benzodiazepine treatment is 
a downregulation of receptor number, this is not sup-
ported within the literature (for review see Uusi Oukari 
and Korpi 2010 and Vinkers and Olivier 2012). Most 
studies demonstrated no modifications following pro-
Fig. 3. The effect of zolpidem treatment and different with-
drawal periods on the expression of GABAAR subunit 
mRNAs: α1, β2 and γ2S. The amount of GABAAR subunits 
mRNA was determined by conventional RT-PCR analysis. 
The maximal optical density of the subunits mRNA expres-
sion was normalized to the expression of reference gene 
β-actin. Data are expressed as means ± SEM. *P<0.05 and 
**P<0.01 versus control group (ANOVA and Dunnett’s 
test).
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longed exposure of cells or animals (Gallagher at al. 
1984, Lewin at al. 1989, Galpern at al. 1991, Primus at 
al. 1996, Toki at al. 1996) and we observed a similar 
result within our experiments. In contrast, Toki and col-
leagues (1996) observed an increase in the maximum 
number of benzodiazepine binding sites at 42 hr after 
diazepam withdrawal. In addition, 4 days after discon-
tinuation of clonazepam (7 days) administration benzo-
diazepine binding in vivo and in vitro, as well as TBPS 
binding, were increased (Galpern at al. 1991). Changes 
in receptor number following zolpidem 96-hour with-
drawal could be a result of interference at several levels: 
increased subunit mRNA transcription, decreased sub-
unit degradation, and/or increased expression of helper 
GABAAR-associated proteins (GABARAP, BIG2, PRIP, 
gephyrin and/or radixin) (for review see Vinkers and 
Olivier 2012). In the group where withdrawal from pro-
longed zolpidem treatment lasted 96 hours we observed 
upregulation of α1 and γ2S subunit mRNA levels while 
β2 mRNA remained at control levels. Although mRNA 
is an intermediate in protein synthesis, we assume that 
the expression of α1 and γ2S polypeptides is also upreg-
ulated since it has been shown that mRNA expression 
correlates with polypeptide expression (Uusi-Oukari at 
al. 2000). Synchronous changes in the expression of α1 
and γ2 subunits after prolonged benzodiazepine treat-
ment have been observed in previous studies (Follesa at 
al. 2002, Biggio at al. 2003, Svob Strac at al. 2008). For 
Fig. 4. The effect of chronic zolpidem treatment and different withdrawal periods on GABA potentiation of [3H]flunitraze-
pam binding to membranes of HEK 293 cells stably transfected with α1β2γ2s subunits of GABAARs. Data are expressed as 
percent of their own basal values (A) and as the maximum GABA-induced enhancements (B; Emax) of [3H]flunitrazepam 
binding. The points (error bars not shown due to clarity) and bars are means ± SEM (n=3–5). *P<0.05 **P<0.01 versus 
control group (ANOVA and Dunnett’s test).
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α1 (Kang at al. 1994) and γ2 (Holt at al. 1997) subunits 
the comparative transcriptional activity and changes in 
mRNA steady-state levels following prolonged benzo-
diazepine exposure have been detected. Since both α1 
(but also α2,3,5) and γ2 subunits are essential for ben-
zodiazepine binding and pharmacology (Rudolph at al. 
1999) one can speculate that the increase in the maxi-
mum number of benzodiazepine binding sites occurred 
probably due to the partial formation of αγ binary forms 
in the group withdrawn from zolpidem treatment for 96 
hours.
The observed increase in the mRNA for α1 and γ2S 
subunits supports our assumption that 96-h withdraw-
al from prolonged zolpidem treatment stimulates de 
novo synthesis of GABAAR proteins. Supporting this, 
it was suggested that the process of GABAAR synthe-
sis has at least some importance in possible alterations 
in subunit expression since the protein synthesis inhib-
itor cycloheximide and the RNA synthesis inhibitor 
actinomycin D abolished the effects of chronic diaze-
pam (Pericic at al. 2007) and flumazenil (Jazvinscak 
Jembrek at al. 2008) treatment. 
In our experimental system chronic zolpidem treat-
ment (10 μM) produced partial uncoupling of allos-
teric interactions between benzodiazepine and GABA 
binding sites as evidenced by a decreased ability of 
GABA to stimulate [3H]flunitrazepam binding. It 
should be mentioned that similar results were also 
obtained with lower (1 μM) zolpidem concentration 
(data not shown). The maximum enhancement of [3H]
flunitrazepam binding produced by GABA was dimin-
ished in groups withdrawn from zolpidem, and espe-
cially in the group where withdrawal lasted for 96 
hours (Fig. 4). In our previous studies we also found 
functional uncoupling of allosteric linkage between 
GABA and benzodiazepine binding sites already after 
two-day zolpidem treatment (Vlainic at al. 2010, 
2012a) whereas in the study of Primus and colleagues 
(1996) decline in the allosteric coupling at recombinant 
GABAA receptors produced by 1 micromolar zolpidem 
concentration is reported. Allosteric uncoupling of 
binding sites is hypothesized as one possible explana-
tion for the decrease of benzodiazepine action at 
GABAAR complex (for review see Bateson 2002 and 
Vinkers and Olivier 2012). There are numerous studies 
indicating such changes after chronic benzodiazepine 
treatment (Roca at al. 1990, Klein at al. 1994, Wong at 
al. 1994, Itier at al. 1996, Primus at al. 1996, Ali and 
Olsen 2001, Pericic at al. 2007, Svob Strac at al. 2008, 
Vlainic at al. 2010, 2012b). As a possible mechanism 
involved in the functional uncoupling of binding sites 
at GABAARs, Ali and Olsen (2001) proposed changes 
in conformation of the receptor. Namely, they assumed 
that chronic benzodiazepine treatment favors a spe-
cific receptor conformation which is a substrate for 
internalization and uncoupling, though the internaliza-
tion of surface receptors was not observed in other 
studies (Primus at al. 1996, Jazvinscak Jembrek at al. 
2008). Moreover, uncoupling could not be prevented at 
GABAARs expressed in cortical neurons even follow-
ing lyses of internal vesicles (Gravielle at al. 2005). It 
has been suggested that the uncoupling occurs in sev-
eral steps where an initial internalization of receptors 
is followed by activation of signaling pathway(s) that 
might lead to selective changes in receptor subunit 
assembly (Gutierrez at al. 2014). This hypothesis is at 
least partially suspect since functional uncoupling of 
GABA and benzodiazepine binding sites following 
prolonged treatment with benzodiazepines (Klein at al. 
1994, 1995, Wong at al. 1994, Primus at al. 1996, 
Pericic at al. 2007, Svob Strac at al. 2008) or zolpidem 
(Vlainic at al. 2010, 2012a) was detected with recom-
binant GABAARs with a specific subunit composition 
where a subunit switch could not occur. Therefore, we 
hypothesize that uncoupling at recombinant stably 
transfected GABAARs could involve either posttrans-
lational modifications of GABAAR proteins or changes 
in subunit stoichiometry. Internalization of receptors 
in intracellular vesicles where benzodiazepine but not 
GABA binds to its site could be presumably also 
excluded, since several studies showed that following 
chronic drug treatment receptors remain at the cell 
surface (Primus at al. 1996, Pericic at al. 2007, 
Jazvinscak Jembrek at al. 2008). Another proposed 
mechanism is the alteration of the receptor itself 
through different phosphorylation status which can 
influence channel openings and/or receptor traffick-
ing. Namely, Lilly and colleagues (2003) found cAMP-
dependent protein kinase A (PKA) activity dysfunc-
tion following chronic flurazepam treatment. Moreover, 
Gutierrez and colleagues (2014) in their experiments 
detected blocking of uncoupling induced by inhibitors 
of protein kinases A and C, indicating that the uncou-
pling is mediated by the activation of a phosphoryla-
tion cascade. 
Dissociation constant (Kd) is the equilibrium con-
stant for the dissociation of a complex into its compo-
nents. Since the dissociation constant for a particular 
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ligand-receptor interaction is affected by different con-
ditions, one might assume that zolpidem treatment and 
its withdrawal could change the strength of intermo-
lecular interactions which holds a particular ligand-re-
ceptor complex together. However, in our experiments 
there was no significant change regarding zolpidem 
treated and withdrawal groups although we observed a 
slight increase in the affinity of the GABAAR (Table 
II). It has been proposed that such, even small altera-
tions in the affinity of GABAAR might influence the 
modulation of 36Cl- efflux, e.g. by decreasing GABA-
stimulated chloride influx (Toki at al. 1996).
CONCLUSIONS
This study showed that chronic zolpidem treatment 
produces no changes in either the number of benzodi-
azepine binding sites or in the expression of GABAAR 
subunits mRNA. In addition, our results demonstrate 
that zolpidem withdrawal has differing effects depend-
ing on the withdrawal duration. Namely, 24, 48 and 72 
withdrawal periods have no effects on the number or 
the expression of mRNA, while the withdrawal period 
of 96 hours produced an upregulation of [3H]fluni-
trazepam binding sites along with an enhancement of 
α1 and γ2S mRNAs suggesting an increased synthesis 
of receptor proteins. Simultaneously, prolonged zolpi-
dem treatment as well as its withdrawal produced an 
uncoupling of GABA and benzodiazepine binding 
sites. This study gives an insight into the potential 
molecular and cellular mechanisms underlying adap-
tive changes of GABAAR function following chronic 
usage of subunit specific GABAergic drugs and one 
might hypothesize that the observed molecular chang-
es could be linked to zolpidem tolerance and depen-
dence produced upon its prolonged treatment.
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